Want to see DCGO full AI Analyst Report?
DCGO Stock Chart & Stats
$0.60
-$0.07(-11.07%)
At close: 4:00 PM EDT
$0.60
-$0.07(-11.07%)
Day’s Range― - ―
52-Week Range$0.45 - $1.78
Previous CloseN/A
Volume791.43K
Average Volume (3M)1.03M
Market Cap
$64.18M
Enterprise Value$33.85
Total Cash (Recent Filing)$35.68M
Total Debt (Recent Filing)$28.51M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 10, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding98,778,410
10 Day Avg. Volume539,160
30 Day Avg. Volume1,029,501
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.60
Price to Sales (P/S)0.27
P/FCF Ratio3.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.38Price Target Upside295.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$306.31M
Bulls Say, Bears Say
Bulls Say
Volume & Revenue MomentumManagement raised full‑year 2026 revenue guidance and reported record volumes across business lines. Excluding one‑off migrant revenue, underlying revenue and visit volumes are expanding, signaling durable demand from contracted programs and an ability to scale care delivery over coming quarters.
Contract Wins & RenewalsDocGo continues to win and renew B2B/B2G contracts, including large hospital system renewals and an NHS nonemergency transport contract. These multi‑period contracts provide recurring service fees and sticky revenue streams, supporting stable utilization and longer‑term program economics.
Stable Gross MarginsDespite revenue and operating swings, consolidated gross margins remain near 30%, reflecting resilient unit economics in medical transportation and mobile health services. Stable unit margins give management room to drive operating leverage as volumes grow and SG&A efficiencies materialize.
Bears Say
Cash‑flow CollapseTrailing‑twelve‑month cash generation deteriorated to very large negative operating and free cash flow, creating acute liquidity and funding risk. Persistent cash burn would force financing, hinder investments, or constrain contract execution if collections and working capital aren’t stabilized.
Deteriorating ProfitabilityOperating performance swung from modest profits to sizable losses, with widened adjusted EBITDA deficits and negative ROE. Continued operating losses reduce internal capital for growth, increase reliance on external funding, and raise execution risk for planned margin recovery initiatives.
Revenue Concentration & AR TimingHistoric reliance on large, nonrecurring migrant programs and delayed collections (material AR outstanding) create revenue timing and working‑capital sensitivity. This concentration and receivable volatility make near‑term cash and revenue less predictable, stressing operations during transition periods.
DocGo News
DCGO FAQ
What was DocGo, Inc.’s price range in the past 12 months?
DocGo, Inc. lowest stock price was $0.45 and its highest was $1.78 in the past 12 months.
What is DocGo, Inc.’s market cap?
DocGo, Inc.’s market cap is $64.18M.
When is DocGo, Inc.’s upcoming earnings report date?
DocGo, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 9 days.
How were DocGo, Inc.’s earnings last quarter?
DocGo, Inc. released its earnings results on May 11, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.122 by -$0.028.
Is DocGo, Inc. overvalued?
According to Wall Street analysts DocGo, Inc.’s price is currently Undervalued.
Does DocGo, Inc. pay dividends?
DocGo, Inc. does not currently pay dividends.
What is DocGo, Inc.’s EPS estimate?
DocGo, Inc.’s EPS estimate is -0.1.
How many shares outstanding does DocGo, Inc. have?
DocGo, Inc. has 98,778,410 shares outstanding.
What happened to DocGo, Inc.’s price movement after its last earnings report?
DocGo, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.122. Following the earnings report the stock price went up 0.507%.
Which hedge fund is a major shareholder of DocGo, Inc.?
Currently, no hedge funds are holding shares in DCGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DocGo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.38 (295.83% Upside)
$2.38 (295.83% Upside)
Blogger Sentiment
Bullish
DCGO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 125.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-51.43%
Trailing 12-Months
Company Description
DocGo, Inc.
DocGo Inc. is a company dedicated to providing mobile healthcare solutions and medical transportation for a wide array of healthcare organizations in both the United States and the United Kingdom. Their transportation portfolio includes critical emergency response, alongside routine non-emergency transfers facilitated by ambulance and specialized wheelchair-accessible vehicles. Additionally, DocGo offers a range of mobile health services, delivered directly to patients' homes and offices through its advanced digital platform. These services further extend to include COVID-19 diagnostic testing and comprehensive on-site healthcare support for various events, such as large sporting competitions and concerts. The company was founded in 2015 and is headquartered in New York, New York.
DCGO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong top‑line momentum and operational wins (raised full‑year revenue outlook, record volumes, SteadyMD acceleration, mobile phlebotomy and care‑gap scale) balanced against meaningful near‑term profitability and cash challenges (wider adjusted EBITDA loss, margin headwinds from fuel and temporary labor incentives, and $13M of outstanding receivables). Management expects many of the margin and expense pressures to be temporary and the majority of cost savings to flow through by Q3, while growth initiatives and contract renewals support the updated revenue guidance.View all DCGO earnings summariesDCGO Stock 12 Month Forecast
Average Price Target
$2.38
▲(295.83% Upside)
Technical Analysis
Ownership Overview
6.99% Insiders
8.26% Mutual Funds
7.73% Other Institutional Investors
72.38% Public Companies and
Individual Investors